The dual‐hormone edge that breaks the 14% wall 💪

How one man lost ~50 lbs on Zepbound while his Ozempic buddy regained it 😱

Author

Federick Gonzalez
March 03, 2026

Hey man,

Remember Joe from the last email?

Still stuck at his 14% wall...

Well, meet his polar opposite.

Richard.

A 49-year-old tech CEO from Austin...

Who discovered the "Zepbound advantage" that changed everything. 💡

While Joe's still injecting Ozempic every morning...

...praying for a miracle...

Richard's down 50 pounds and counting.

The secret?

His golf buddy Mike...

Same age...

Same starting weight...

Started Ozempic the same week Richard started Zepbound...

Mike lost 30 lbs in 4 months on Ozempic.

Then gained back 35. 📈

Ouch.

The Double-Hormone Demolition

Here's what nobody tells you about weight loss drugs...

Ozempic is like sending one Army soldier into battle...

Zepbound?

That's Army DELTA Force. 😎 

It hits TWO hormone receptors at once:

  • GLP-1 (like Ozempic)

  • GIP (the secret weapon)

This dual-action assault creates what researchers call...

"Synergistic metabolic activation."

Translation: stronger feel-fuller signals—and glycemic control from GLP‑1 + GIP working together.

In SURPASS‑2 (type 2 diabetes) trial...

semaglutide ~13.7% vs tirzepatide ~21.4%...

average weight loss at 40–52 weeks.

That’s a materially larger average reduction in that trial. [2]

The Muscle-Saving Magic

But here's where it gets REALLY interesting...

Remember Mike who gained everything back?

Turns out he lost mostly muscle on Ozempic.

When he stopped...

His metabolism was TOAST. 🍞

Richard?

Totally different story.

Emerging analyses suggest...

tirzepatide programs may better preserve lean mass...

versus GLP‑1 alone in some cohorts.[3][7]

It's sorta like a construction crew that ONLY demolishes fat...

...while leaving your muscle fortress intact. 🏰

Here's Zepbound's Royal Flush:

♦️♦️♦️♦️♦️

Maker: Eli Lilly Pharmaceutical. Founded 1876. HQ Indianapolis, Indiana.

Founder: Colonel Eli Lilly, a pharmaceutical chemist and Civil War veteran.

Name Brand: Zepbound

Molecule: tirzepatide

Class: first FDA‑approved dual GLP‑1/GIP agonist. 

Targets both:

• GIP (glucose-dependent insulinotropic polypeptide)

• GLP-1 (glucagon-like peptide-1) hormone receptors.

How does it work: Lowers appetite. Eat less. Feel fuller. Less cravings.

Secondary benefits: Stabilizes blood sugar. Better insulin management. Improves sleep apnea. [17]

How taken: single‑patient pen or vial. (Syringe/Needle).

Or new—Four-dose single-patient KwikPen.

How often: Weekly dosing per label.

Price: Availability and pricing vary by program and pharmacy.

Check your plan or LillyDirect for details.

2026 Pricing: Starts at $299. Same price for single or quad multi-dose. Tip: Choose the KwikPen option.

Dosages: 2.5 mg. 5 mg. 10 mg. 15 mg.

Direct-to-consumer (DTC) option: Yes. Via LillyDirect.

Your Zepbound Battle Plan

Before you jump ship from Ozempic...

Get these critical numbers checked:

TEST #1: Body Composition (DEXA Scan)

  • Track body comp via DEXA to see fat vs lean changes.

  • Shows you EXACTLY how much muscle vs fat you carry [13]

  • Critical for tracking what you're actually losing [14]

  • Optimal muscle mass: 35-40% of body weight for men over 40 [4]

TEST #2: Resting Metabolic Rate (RMR)

  • Use a RMR test to establish your baseline.


    Low readings signal you to focus on protein and resistance training.

  • How many calories you burn at rest [15]

  • Men 40-50: Should be ~1,600 - 1,800 calories/day [5]

  • Below 1,500? Your metabolism needs rescue

TEST #3: C-Peptide

  • Measures it in blood or urine.


    Shows how much insulin your pancreas makes naturally

  • Normal range: 0.5 - 2.70 ng/mL [6]

  • Predicts your response to GLP-1 drugs

RANGES THAT REVEAL YOUR DESTINY:

Here's what separates the Richards from the Mikes...

Weight Loss Speed by Drug (according to clinical trials):

  • Ozempic: 1-2 lbs/week first 3 months, then slows [1][11]

  • Zepbound: 2-3 lbs/week sustained for 6+ months. SURMOUNT-1: Up to 22.5% loss over 72 weeks. [2][12]

  • Remember—in programs weekly loss varies widely by dose ... adherence ... and population.

    Averages are better expressed by total percent change at trial endpoints.

  • Muscle preservation: Zepbound saves more lean mass [7]

Weight Regain Risk After Stopping: [16]

  • After GLP‑1 withdrawal, significant regain is common without sustained habits. [8]

    Your defense is skills: protein, resistance training, and calibrated calories while tapering. [16]

  • With muscle maintenance: Live longer. Lower fat weight.


    Better glucose metabolism. Lower risk of diabetes [9][10]

Warning.

A new meta Oxford study—identifies a "skills gap" as the main reason for weight regain. [16]

People using weight loss drugs...

Ozempic ...

Zepabound ...

Retritrutide ...

... points to behavior change gaps as a driver of weight regain—after medication use stops. [16]

Skills beat willpower: plan protein, lift, and keep structure as appetite returns.

Versus guys already used to the "diet and exercise" discipline developed over years.

This making sense?

Good.

So, when the biological "appetite brake" of the medication is removed...

Meaning—You're off Ozempic/Zepabound/Retitrutide...

and you're not used to "dieting or hitting the gym"...

you regain the weight.

So what's Richard's secret?

He didn't just switch drugs...

He followed the "Zepbound Protocol":

• Week 1-4: Low dose ramp-up (2.5mg)

• Week 5‑8: Dose titration per label and tolerance (often 5–7.5 mg)

• Week 9+: Cruise control (10–15mg based on response)

Plus strategic protein timing...

And resistance training 3x/week.

The result?

Richard tracked DEXA while dropping from 285 to 235...

and reports a small lean‑mass uptick alongside fat loss. 💪

Your Move, bro.

Arnold knows. Do you?

What's your biggest fear about switching from Ozempic?

A) Losing progress I've made

B) Side effects getting worse

C) Cost difference

D) My doctor won't prescribe it

Reply with A, B, C, or D...

And I'll send you the exact script that got Richard's doctor on board.

To your transformation,

Mens Health Secrets 
–Live Past 100

P.S. Next email reveals... Wegovy’s 2.4 mg program and adherence strategy many miss—and how to avoid the plateau patterns... that kill results.

P.P.S. Always check with your primary physician first. Especially when starting any weight-loss treatment. This is for education + entertainment (edutainment) only. We assume no liability. 

P.P.P.S. YT: (link) + comment “Ozempic” to Level up.

P.P.P.P.S. New Skool group: Free for life (Q2 price activates). Reply "TRIBE." Your Bros ready.

Medical References:

[1] Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Kahn, S. E., Kahn, J., Lingvay, I., ... & Mann, J. F. E. (2024). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 390(19), 1767-1778. https://doi.org/10.1056/NEJMoa2307563 (SELECT trial: 20% reduction in major CV events; ~10% average weight loss over 208 weeks in non-diabetics.)

[2] Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. https://doi.org/10.1056/NEJMoa2107519

[3] Farzam K, Patel P. Tirzepatide. [Updated 2024 Feb 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK585056/

[4] Bennett JP, Lim S. The Critical Role of Body Composition Assessment in Advancing Research and Clinical Health Risk Assessment across the Lifespan. J Obes Metab Syndr. 2025 Apr 30;34(2):120-137. https://doi.org/10.7570/jomes25010. Epub 2025 Apr 8. PMID: 40194886; PMCID: PMC12067000.

[5] Mayo Clinic. (2024). Metabolism and weight loss: How you burn calories. https://www.mayoclinic.org/healthy-lifestyle/weight-loss/in-depth/metabolism/art-20046508

[7] Hidalgo Ramos RA, Hong I, Ortiz M, Secades D, Dufner Krieger S, Ramos Stanziola L. Effects of Tirzepatide on Skeletal Muscle Mass in Adults: A Systematic Review. Cureus. 2025 Jul 29;17(7):e89020. https://doi.org/10.7759/cureus.89020. PMID: 40895971; PMCID: PMC12394919.

[8] Wilding, J. P., Batterham, R. L., Davies, M., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism, 24(8), 1553-1564. https://doi.org/10.1111/dom.14725

[9] Westcott WL. Resistance training is medicine: effects of strength training on health. Curr Sports Med Rep. 2012 Jul-Aug;11(4):209-16. https://doi.org/10.1249/JSR.0b013e31825dabb8. PMID: 22777332.

[10] Momma H, Kawakami R, Honda T, et al Muscle-strengthening activities are associated with lower risk and mortality in major non-communicable diseases: a systematic review and meta-analysis of cohort studies British Journal of Sports Medicine 2022;56:755-763. https://bjsm.bmj.com/content/56/13/755

[11] Kommu S, Whitfield P. Semaglutide. [Updated 2024 Feb 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK603723/

[12] Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., ... & SURMOUNT-1 Study Group. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. https://doi.org/10.1056/NEJMoa2206038 (SURMOUNT-1: Up to 22.5% loss over 72 weeks.)

[13] Shepherd JA, Ng BK, Sommer MJ, Heymsfield SB. Body composition by DXA. Bone. 2017 Nov;104:101-105. https://doi.org/10.1016/j.bone.2017.06.010. Epub 2017 Jun 16. PMID: 28625918; PMCID: PMC5659281.

[14] UC Davis Health. (n.d.). DXA body composition analysis. https://health.ucdavis.edu/sports-medicine/resources/dxa-info

[15] Kim DK. Accuracy of predicted resting metabolic rate and relationship between resting metabolic rate and cardiorespiratory fitness in obese men. J Exerc Nutrition Biochem. 2014 Mar;18(1):25-30. https://doi.org/10.5717/jenb.2014.18.1.25. Epub 2014 Feb 28. PMID: 25566436; PMCID: PMC4241941.

[16] West S, Scragg J, Aveyard P, Oke J L, Willis L, Haffner S J P et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis BMJ 2026; 392 :e085304 https://doi.org/10.1136/bmj-2025-085304.

[17] Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, Sands SA, Schwab RJ, Dunn JP, Chakladar S, Bunck MC, Bednarik J; SURMOUNT-OSA Investigators. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024 Oct 3;391(13):1193-1205. doi: 10.1056/NEJMoa2404881. Epub 2024 Jun 21. Erratum in: N Engl J Med. 2024 Oct 17;391(15):1464. https://doi.org/10.1056/NEJMx240005. PMID: 38912654; PMCID: PMC11598664.